The complex relationship between BRCA1 and ERα in hereditary breast cancer

Clinical Cancer Research

Volumn 15, Issue 5, 2009, Pages 1514-1518

  Gorski, Julia J ^a   Kennedy, Richard D ^a   Hosey, Alison M ^a   Harkin, D Paul ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; BRCA1 PROTEIN; CYCLOHEXIMIDE; ESTROGEN RECEPTOR ALPHA; GOSERELIN; MESSENGER RNA; PROTEIN P300; TAMOXIFEN;

BREAST CANCER; CANCER PREVENTION; DISEASE ASSOCIATION; FAMILIAL CANCER; GENE MUTATION; HETEROZYGOTE; HUMAN; NONHUMAN; ONCOGENE; OVARIECTOMY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

BRCA1 PROTEIN; BREAST NEOPLASMS; ESTROGEN RECEPTOR ALPHA; ESTROGENS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION;

EID: 63549144514     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0640     Document Type: Review

References (51)

1. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Breast Cancer Linkage Consortium. risks of cancer in BRCA1-mutation carriers. Lancet 1994;343: 692-5.
2. Ford D, Easton DF, Stratton M, et al. The Breast Cancer Linkage Consortium. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998;62: 676-89.
3. Easton DF, Ford D, BishopDT. Breast Cancer Linkage Consortium. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Am J Hum Genet 1995;56: 265-71.
4. Thompson D, Easton DF. Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002; 94:1358-65.
5. Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 2002;94:1365-72.
6. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71.
7. Simard J, Tonin P, Durocher F, et al. Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. Nat Genet 1994;8:392-8.
8. Friedman LS, Ostermeyer EA, Szabo CI, et al. Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nat Genet 1994;8:399-404.
9. Seery LT, Knowlden JM, Gee JM, et al. BRCA1 expression levels predict distant metastasis of sporadic breast cancers. Int J Cancer 1999;84:258-62.
10. Esteller M, Silva JM, Dominguez G, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 2000; 92:564-9.
11. Butcher DT, Rodenhiser DI. Epigenetic inactivation of BRCA1 is associated with aberrant expression of CTCF and DNA methyltransferase (DNMT3B) in some sporadic breast tumours. Eur J Cancer 2007; 43:210-9.
12. Stone C, McCabe N, Ashworth A. X-chromosome inactivation: X marks the spot for BRCA1. Curr Biol 2003;13:R63-4.
13. Mullan PB, Quinn JE, Harkin DP. The role of BRCA1 in transcriptional regulation and cell cycle control. Oncogene 2006;25:5854-63.
14. Ruffner H, Joazeiro CA, Hemmati D, Hunter T, Verma IM. Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity. Proc Natl Acad Sci U S A 2001;98:5134-9.
15. Lakhani SR, Van DeVijver MJ, Jacquemier J, et al. The pathology of familial breastcancer:predictivevalue of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002;20:2310-8.
16. LakhaniSR, Reis-Filho JS, FulfordL,et al. Prediction ofBRCA1statusin patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 2005;11:5175-80.
17. Foulkes WD, Stefansson IM, Chappuis PO, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 2003;95: 1482-5.
18. Ding SL, Sheu LF,Yu JC, et al. Expression of estrogen receptor-a and Ki67 in relation to pathological and molecular features in earlyonset infiltrating ductal carcinoma. J Biomed Sci 2004;11:911 -9.
19. Spillman MA, Bowcock AM. BRCA1 and BRCA2 mRNA levels are coordinately elevated in human breast cancer cells in response to estrogen. Oncogene 1996;13:1639-45.
20. Marks JR, Huper G,Vaughn JP, et al. BRCA1 expression is not directly responsive to estrogen. Oncogene 1997;14:115-21.
21. Perou CM, Jeffrey SS, van de Rijn M, et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci USA 1999;96:9212-7.
22. SorlieT, Perou CM,Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869-74.
23. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003; 100:8418-23.
24. Marquis ST, Rajan JV, Wynshaw-BorisA,etal. The developmental pattern of Brca1 expression implies a role in differentiation of the breast and other tissues. Nat Genet 1995;11:17-26.
25. Lane TF, Deng C, Elson A, Lyu MS, Kozak CA, Leder P. Expression of Brca1 is associated with terminal differentiation of ectodermally and mesodermally derived tissues in mice. Genes Dev 1995;9:2712-22.
26. Jeffy BD, Hockings JK, KempMQ, et al. An estrogen receptor-a/p300 complex activates the BRCA-1 promoterat an AP-1 site that binds Jun/Fos transcription factors: repressive effects of p53 on BRCA-1 transcription. Neoplasia 2005;7:873-82.
27. HockingsJK,Thorne PA, KempMQ, Morgan SS, Selmin O, RomagnoloDF. The ligand status of the aromatic hydrocarbon receptor modulates transcriptional activation of BRCA-1 promoter by estrogen. Cancer Res 2006;66:2224-32.
28. Fan S, Wang J, Yuan R, et al. BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science 1999;284:1354-6.
29. Xu J, Fan S, Rosen EM. Regulation of the estrogeninducible gene expression profile by the breast cancer susceptibility gene BRCA1. Endocrinology 2005;146: 2031 -47.
30. Zheng L, Annab LA, Afshari CA, Lee WH, Boyer TG. BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor. Proc Natl Acad Sci U S A 2001;98:9587-92.
31. Fan S, Ma YX, Wang C, et al. Role of direct interaction in BRCA1 inhibition of estrogen receptor activity. Oncogene 2001;20:77-87.
32. FanS,Ma YX, Wang C, et al.p300 Modulates the BRCA1 inhibition of estrogen receptor activity. Cancer Res 2002;62:141-51.
33. Kawai H, Li H, Chun P, Avraham S, Avraham HK. Direct interaction between BRCA1 and the estrogen receptor regulates vascular endothelial growth factor (VEGF) transcription and secretion in breast cancer cells. Oncogene 2002;21:7730-9.
34. Johannsson OT, Idvall I, Anderson C, et al. Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer 1997;33:362-71.
35. 35. Verhoog LC, Brekelmans CT, Seynaeve C, et al. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet 1998;351:316-21.
36. Hosey AM, Gorski JJ, Murray MM, et al. Molecular basis for estrogen receptor a deficiency in BRCA1-linked breast cancer. J Natl Cancer Inst 2007;99: 1683-94.
37. Liu S, Ginestier C, Charafe-Jauffret E, et al. BRCA1 regulates human mammary stem/progenitor cell fate. Proc Natl Acad Sci U S A 2008;105:1680-5.
38. Turner N,Tutt A, Ashworth A. Hallmarks of 'BRCA-ness' in sporadic cancers. Nat Rev Cancer 2004;4: 814-9.
39. Wirk B. The role of ovarian ablation in the management of breast cancer. Breast J 2005;11:416-24.
40. Meijers-Heijboer H, Brekelmans CT, Menke-Pluymers M, et al. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation. J Clin Oncol 2003;21: 1675-81.
41. Kucera E, Holub Z, Svobodova G. Laparoscopic oophorectomy either with or without hysterectomy for early breast cancer. Eur J Gynaecol Oncol 2007; 28:294-6.
42. Early Breast Cancer Trialists 'Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451 -67.
43. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90: 1371 -88.
44. Cuzick J, PowlesT,Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003;361:296-300.
45. Narod SA, Brunet JS, Ghadirian P, et al. Hereditary Breast Cancer Clinical Study Group. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Lancet 2000;356:1876-81.
46. Eisen A, Lubinski J, Klijn J, et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol 2005;23:7491 -6.
47. Domchek SM, Rebbeck TR. Prophylactic oophorectomy in women at increased cancer risk. Curr Opin Obstet Gynecol 2007;19:27-30.
48. RebbeckTR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002;346:1616-22.
49. Folkerd EJ, Martin LA, Kendall A, Dowsett M. The relationship between factors affecting endogenous oestradiol levels in postmenopausal women and breast cancer. J Steroid Biochem Mol Biol 2006;102: 250-5.
50. Kaaks R, Rinaldi S, Key TJ, et al. Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocr Relat Cancer 2005;12: 1071 -82.
51. Miller WR. Aromatase inhibitors: mechanism of action and role in the treatment of breast cancer. Semin Oncol 2003;30:3-11.